The effect of bodyweight on the efficacy and safety of ixekizumab: results from an integrated database of three randomised, controlled Phase 3 studies of patients with moderate‐to‐severe plaque psoriasis
K. Reich; L. Puig; L. Mallbris; L. Zhang; O. Osuntokun; C. Leonardi
Author Information: Dermatologikum Hamburg and SCIderm Research Institute
|Checking for direct PDF access through Ovid|
Abstract unavailable for this article.